stockrow
Monday 9 November 2026
Export LRMR’s income statement to Excel — free account
Larimar Therapeutics, Inc.
LRMR- EPS
- +26.8%
- Free cash flow
- −127.6%
Quarter to June 2026, against a year earlier
2.39
0.07
+3.02%
Follow LRMR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | 42 | 130 | +212.4% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (58) | (52) | (61) | (23) | (42) | (51) | (35) | (37) | (81) | (166) | (173) | +12.4% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (58) | (52) | (61) | (23) | (42) | (51) | (35) | (37) | (81) | (166) | (173) | +12.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (25.45) | (22.81) | (22.81) | (3.80) | (3.57) | (2.95) | (1.37) | (0.84) | (1.32) | (2.27) | (1.95) | (23.6%) | ||||||
| Cash flow | (22.86) | (19.16) | (19.18) | (3.73) | (3.55) | (2.45) | (1.07) | (0.76) | (1.16) | (1.55) | (1.50) | (25.8%) | ||||||
| Capex | (0.29) | (0.02) | (0.04) | (0.01) | (0.01) | (0.02) | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | (45.7%) | ||||||
| Free cash flow | (23.15) | (19.18) | (19.22) | (3.74) | (3.56) | (2.47) | (1.07) | (0.77) | (1.16) | (1.55) | (1.50) | (25.9%) | ||||||
| Book value | 53.53 | 34.23 | 34.74 | (0.11) | 7.55 | 3.75 | 4.31 | 1.86 | 2.80 | 1.07 | 1.23 | (35.3%) | ||||||
| Shares, m | 2 | 2 | 3 | 6 | 12 | 17 | 26 | 44 | 61 | 73 | 86 | +47.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (52) | (44) | (51) | (23) | (42) | (42) | (28) | (33) | (71) | (113) | (156) | +9.0% | |||||
| Capex | (1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1) | 0 | 0 | (19.8%) | ||||||
| Free cash flow | (53) | (44) | (52) | (23) | (42) | (42) | (28) | (34) | (71) | (113) | (156) | +8.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 121 | 98 | 108 | (1) | 89 | 63 | 110 | 81 | 171 | 77 | 127 | (4.9%) | |||||
| Net debt | (129) | (82) | (103) | (1) | (93) | (70) | (118) | (87) | (183) | (137) | (156) | +0.6% | ||||||
| Shareholders’ equity | 122 | 78 | 93 | (1) | 90 | 64 | 111 | 82 | 172 | 78 | 127 | (4.8%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (36.09) | (43.88) | (54.00) | (36.44) | (77.32) | (55.23) | (34.48) | (33.24) | (54.43) | (95.75) | (108.53) | (59.7) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (39.80) | (52.04) | (71.57) | (49.97) | (95.47) | (65.72) | (40.33) | (38.36) | (63.58) | (132.59) | (138.41) | (92.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 32 | 35 | 38 | 7 | 28 | 31 | 26 | 42 | 65 | 71 | — | +9.3% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Larimar Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| QTTB Q32 Bio Inc. | $276.8M | 3.1× | — (loss-making) | −1,928.18% (below 0%: shrinking) | n/m | +71.13% (above 0%: growing) | 100.00% | 0.00% | Compare |
| LCTX Lineage Cell Therapeutics, Inc. | $258.0M | — (loss-making) | — (loss-making) | −61.34% (below 0%: shrinking) | n/m | −32.40% (below 0%: shrinking) | 100.00% | (834.71%) | Compare |
| CUVL Clinuvel Pharmaceuticals Ltd. - Sponsored ADR | $257.5M | — | — | — | — | — | — | — | Compare |
| CAMP CAMP4 Therapeutics Corporation | $254.8M | — (loss-making) | — (loss-making) | +138.87% (above 0%: growing) | n/m | +20.36% (above 0%: growing) | 100.00% | (738.76%) | Compare |
| LRMR Larimar Therapeutics, Inc. | $248.3M | — (loss-making) | — | — | n/m | −127.63% (below 0%: shrinking) | 0.00% | 0.00% | |
| EVMN Evommune Inc. | $241.3M | — (loss-making) | — (loss-making) | — | n/m | +21.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ABEO Abeona Therapeutics Inc. | $238.5M | — (loss-making) | — (loss-making) | +225.14% (above 0%: growing) | n/m | +17.11% (above 0%: growing) | 63.30% | (119.97%) | Compare |
| LXEO Lexeo Therapeutics, Inc. | $237.2M | — (loss-making) | — (loss-making) | — | n/m | +35.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| FATE Fate Therapeutics, Inc. | $223.1M | — (loss-making) | — (loss-making) | +9.18% (above 0%: growing) | n/m | +8.96% (above 0%: growing) | 100.00% | (1,495.39%) | Compare |
| Median of peers | $248.1M | — | — | +9.18% | — | +20.36% | 100.00% | (119.97%) |
Pay and ownership Proxy statement filed 20 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 3.53m | 2.14m | 36.24 |
| 2024 | 2.51m | 2.44m | 35.87 |
| 2023 | 3.14m | 3.26m | 42.17 |
Ownership
Directors and executive officers, together
4.00%
Entities affiliated with Deerfield Management
34.30%
Blue Owl Capital Holdings LP
8.10%
Millennium Management LLC
5.00%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement